logo
Search
Close this search box.
Search
Close this search box.

Non-culture based testing guidelines from the CDC/NHSN

T2 Biosystems' Panels will NOT increase your CLABSI rates for patients tested in conjunction with blood culture testing

Effective January 1, 2020, new guidance has been provided for the use of non-culture based testing methodologies (NCT) as it relates to laboratory-confirmed bloodstream infections (LCBI). If blood is collected for culture within 2 days before, or 1 day after the NCT, disregard the result of the NCT and use ONLY the result of the culture to make an LCBI surveillance determination. If no blood is collected for culture within this time period, use the result of the NCT for LCBI surveillance determination.1

If blood cultures are collected…

Species identification in just hours: Data generated by T2Bacteria users demonstrate its ability to benefit patients in the emergency department by providing information that leads to more rapid time to delivery of effective therapy, de-escalation of unnecessary therapy, and helping avoid premature discharge and readmission to the emergency department.2

With T2Candida, multiple hospitals have shown that making targeted treatment decisions faster leads to improved outcomes, better stewardship, and reduces the cost of sepsis management. These institutions have independently reported significant reductions in length of stay and antifungal utilization, as well as substantial cost savings.3,4

“The T2Bacteria Test Panel represents a substantial clinical improvement over existing technologies because it reduces the proportion of patients on inappropriate therapy, thus reducing the rate of subsequent diagnostic or therapeutic intervention as well as length of stay and mortality rates caused by sepsis causing bacterial infections.”5

……………………………………….

1. CDC/NHSN Patient Safety Component Manual, 2019.
2. Voigt, Christopher, et al. “The T2Bacteria assay Is a sensitive and rapid detector of bacteremia that can be initiated in the emergency department and has potential to favorably influence subsequent therapy.” The Journal of emergency medicine 58.5 (2020): 785-796.
3. Wilson, N.M. et. al. Poster Presentation IDWeek 2016.
4. Estrada, S. J. Slide Presentation ASM 2016.
5. United States CMS FY 2020 inpatient prospective payments system final rule

CONTACT US

T2 Biosystems
101 Hartwell Avenue
Lexington, MA 02421
Phone: 781-457-1200
Fax: 781-357-3080